https://t-5224inhibitor.com/ep....ithelial-mesenchymal
Changes in PromarkerD scores (a key metric) in T2D individuals treated with canagliflozin over a three-year period were evaluated in the CANagliflozin cardioVascular Assessment Study (CANVAS). Participants enrolled in the 2008 study, with baseline eGFR of 60 mL/min/1.73 m2 and preserved kidney function, had their PromarkerD scores evaluated at baseline and three years later. Generalized estimating equations were applied to study how c
Aimer
Commentaire
Partagez
